Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nishan Tchekmedyian

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Current Opinion in Oncology|May 5, 2009
Utilization of positron emission tomography in the management of patients with sarcomaMatthias R Benz, Nishan Tchekmedyian, Fritz C Eilber, et al.
Breast Cancer Research and Treatment|February 3, 2007
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitroRichard S Finn, Judy Dering, Charles Ginther, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case seriesNishan Tchekmedyian, Raja Mudad, Fernando F Blanco, et al.
Oncology (Williston Park, N.Y.)|December 19, 2015
Propelling Immunotherapy Combinations Into the ClinicNishan Tchekmedyian, Jhanelle E Gray, Benjamin C Creelan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2021
Poziotinib in Non-Small-Cell Lung Cancer Harboring <i>HER2</i> Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 TrialXiuning Le, Robin Cornelissen, Marina Garassino, et al.
BMJ Open|September 14, 2022
Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trialDaniel J George, David R Spigel, Lucio N Gordan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 4, 2020
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLCViola W Zhu, Yen-Ting Lin, Dong-Wan Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2019
Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung CancerJhanelle E Gray, Andreas Saltos, Tawee Tanvetyanon, et al.
Nature Communications|September 24, 2025
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivityXiuning Le, Jacqulyne P Robichaux, Monique Nilsson, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Current Opinion in Oncology|May 5, 2009
Utilization of positron emission tomography in the management of patients with sarcomaMatthias R Benz, Nishan Tchekmedyian, Fritz C Eilber, et al.
Breast Cancer Research and Treatment|February 3, 2007
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitroRichard S Finn, Judy Dering, Charles Ginther, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case seriesNishan Tchekmedyian, Raja Mudad, Fernando F Blanco, et al.
Oncology (Williston Park, N.Y.)|December 19, 2015
Propelling Immunotherapy Combinations Into the ClinicNishan Tchekmedyian, Jhanelle E Gray, Benjamin C Creelan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2021
Poziotinib in Non-Small-Cell Lung Cancer Harboring <i>HER2</i> Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 TrialXiuning Le, Robin Cornelissen, Marina Garassino, et al.
BMJ Open|September 14, 2022
Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trialDaniel J George, David R Spigel, Lucio N Gordan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 4, 2020
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLCViola W Zhu, Yen-Ting Lin, Dong-Wan Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2019
Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung CancerJhanelle E Gray, Andreas Saltos, Tawee Tanvetyanon, et al.
Nature Communications|September 24, 2025
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivityXiuning Le, Jacqulyne P Robichaux, Monique Nilsson, et al.
Pageof 1